prevalence of cvd and assessment of cv risk in patients with prostate cancer
Published 7 years ago • 299 plays • Length 20:48Download video MP4
Download video MP3
Similar videos
-
5:08
cardiovascular & metabolic risk profiles of hormonal agents for managing advanced prostate cancer
-
27:50
new concepts in adt
-
11:48
cardiovascular implications in the treatment of prostate cancer
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
11:16
cardiovascular complications in patients undergoing adt
-
24:41
testosterone therapy, the fda, and cvd risk controversies
-
10:47
exercise and prostate cancer: prevention and bettering outcomes in localized and advanced disease
-
5:06
va starport prostate cancer clinical trial
-
18:33
sarcopenia in the prostate cancer patient
-
10:51
advanced prostate cancer clinical trials update 2022
-
14:18
prostate inflammation and prostate cancer: what do i need to know?
-
6:18
updates of changes in the early detection of prostate cancer nccn guidelines 2021
-
27:05
adt for prostate cancer: agonists vs antagonists
-
13:25
progess in understanding pathology of prostate cancer
-
1:07:32
module 1 cvd in prostate cancer patients increased risks & comorbidities
-
19:56
recognizing and managing side effects of androgen deprivation therapy (adt)
-
56:34
1/13/17 grand rounds: diet, drugs and steel: rheumatology update for the internist
-
21:44
erectile dysfunction and the detection of subclinical cardiovascular disease
-
51:42
2/2/18: androgen deprivation therapy in prostate cancer: adverse effects and strategies to mitigate